Off-label prescribing among office-based physicians

Archives of Internal Medicine

Volumn 166, Issue 9, 2006, Pages 1021-1026

  Radley, David C ^a   Finkelstein, Stan N ^b,d   Stafford, Randall S ^c  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXICILLIN; ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; AZITHROMYCIN; CIPROFLOXACIN; DEXAMETHASONE; DIGOXIN; FAMOTIDINE; GABAPENTIN; IPRATROPIUM BROMIDE; ISOSORBIDE MONONITRATE; METHYLPREDNISOLONE; NORTRIPTYLINE; RISPERIDONE; SALBUTAMOL; SALBUTAMOL SULFATE; TEMAZEPAM;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHYSICIAN; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 33646417326     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.9.1021     Document Type: Article

References (28)

1. Appler WD, McMann GL. View from the nation's capital: "off-label" uses of approved drugs: limits on physicians' prescribing behavior. J Clin Psychopharmacol. 1989;9:368-370.
2. Chavey WE II, Blaum CS, Bleske BE, Van Harrison R, Kesterson S, Nicklas JM. Guideline for the management of heart failure caused by systolic dysfunction, II: treatment. Am Fam Physician. 2001;64:1045-1054.
3. Chen H, Deshpande AD, Jiang R, Martin BC. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638.
4. Loder EW, Biondi DM. Off-label prescribing of drugs in specialty headache practice. Headache. 2004;44:636-641.
5. Hoo GW. Off label, on target? Chest. 2004;126:1022-1025.
6. Nightingale SL. Off-label use of prescription drugs. Am Fam Physician. 2003;68:425-427.
7. Pomerantz JM, Finkelstein SN, Berndt ER, et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry. 2004;65:395-404.
8. Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. Am Fam Physician. 2003;68:498-504.
9. Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:56-62.
10. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25:1-5.
11. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000;83:498-501.
12. Rayburn WF, Turnbull GL. Off-label drug prescribing on a state university obstetric service. J Reprod Med. 1995;40:186-188.
13. Donofrio PD, Busis NA. Regulatory and reimbursement issues in treating patients with immune-mediated neuropathies. Neurology. 2002;59:S41-S45.
14. Strom BL, Melmon KL, Miettinen OS. Post-marketing studies of drug efficacy: why? Am J Med. 1985;78:475-480.
15. IMS HEALTH. National Disease and Therapeutic Index, Medication Reference File, 2001. Plymouth Meeting, Pa: IMS Health; 2001.
16. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
17. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. Available at: http://amstat.org/ sections/srms/Proceedings. Accessed February 27, 2006.
18. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
19. Medical Economics Co. Physicians' Desk Reference: 2002. 56th ed. Montvale, NJ: Medical Economics Co; 2002.
20. Healthcare Series MICROMEDEX. MICROMEDEX Healthcare Series. Greenwood Village, Colo: MICROMEDEX; 2002.
21. Payment for Covered Outpatient Drugs and Biologicals, 69Federal Register 55763 (2004) (codified at 42 CFR §405, 410, 411, 414, 418, 424, 484, 486).
22. Healthcare Series Quarterly Editorial Updates MICROMEDEX. What's New In Vol 113. Greenwood Village, Colo: MICROMEDEX Healthcare Series; 2002.
23. Center for Drug Evaluation and Research. Electronic Orange Book, 2003 Vol: Food and Drug Administration. Available at: http://www.fda.gov/cder/ob. Accessed February 27, 2006.
24. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstien AM. Promotion of prescription drugs to consumers. N Engl J Med. 2003;346:498-505.
25. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
26. Long J, Ervin L. Using heteroscedasticity: consistent standard errors in the linear regression model. Am Stat. 2000;54:217-224.
27. Wilde Mathews A. US gets dose of ideas on drug safety tactics from developed nations: in Europe and elsewhere, vigilance remains high in postapproval stage. Wall Street Journal Europe. December 31, 2004;22(234):1.
28. Larkin M. Warner-Lambert found guilty of promoting Neurontin off label. Lancet Neurol. 2004;3:387.